Hospira wins French biosimilar drug tender at 45 pct discount
Saturday, July 04, 2015
A major French hospital group has chosen a cheap copycat version of a top-selling drug for treating its patients with rheumatoid arthritis and Crohn's disease in a victory for a new type of medicine known as biosimilars.
In a document seen by Reuters, the central purchasing agency for the Assistance Publique - Hôpitaux de Paris (AP-HP) said on Friday it had decided to buy the biosimilar version of infliximab from Hospira, after the company offered an estimated 45 percent discount in a tender.
reuters.com
